DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Prostacyclin's Effect on Platelet Responsiveness

Information source: Catholic University of the Sacred Heart
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Acute Kidney Failure

Intervention: prostacyclin (Drug); heparin (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Catholic University of the Sacred Heart

Official(s) and/or principal investigator(s):
Massimo Antonelli, MD, Study Director, Affiliation: Istituto Anestesia e Rianimazione Università Cattolica Policlinico Gemelli


The researchers investigated the influence of a prostacyclin analogue (PGIA) versus unfractionated heparin (UFH) on ex vivo platelet function, during continuous venovenous hemodiafiltration.

Clinical Details

Official title: Heparin Versus Prostacyclin in Continuous Hemodiafiltration for Acute Renal Failure: Effects on Platelet Responsiveness in the Systemic Circulation and Across the Filter.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Detailed description: Context and purpose of the study: Prospective, randomized comparison of a PGIA versus UFH as circuit anticoagulant. Platelet responsiveness was assessed from peripheral blood by light-transmittance aggregometry (LTA) induced by collagen and ADP, at baseline, 4 and 24 hrs after treatment onset. Platelet function was also assessed in blood samples collected in the circuit before and after the filter. The Setting was a University Hospital Intensive Care Unit. 23 ICU patients with Acute Renal Failure needing CVVHDF were studied during standard CVVHDF therapy, at random infusion in the extracorporeal circuit of PGIA or UFH.


Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- critically patients ill patients with acute kidney failure (AKI) needing renal

replacement therapy Exclusion Criteria:

- therapy with aspirin or other non-steroidal anti-inflammatory drugs in the previous 7


- concomitant treatment with other extracorporeal organ-assist devices any other drug

affecting coagulation or platelets

Locations and Contacts

Policlinico Gemelli, Rome 00168, Italy
Additional Information

Starting date: September 2007
Last updated: April 28, 2009

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017